We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT) (BENEDICT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00235014
Recruitment Status : Completed
First Posted : October 10, 2005
Last Update Posted : July 15, 2008
Information provided by:

Brief Summary:
The BENEDICT study is conducted to examine the effects of an ACE inhibitor, calcium channel blockade, a combination of these, and placebo, in the prevention of micro- and macro-albuminuria in Type 2 diabetic patients.

Condition or disease Intervention/treatment Phase
Hypertension Diabetes Drug: trandolapril Drug: trandolapril/verapamil Drug: placebo Drug: verapamil Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1204 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT)
Study Start Date : March 1997
Primary Completion Date : January 2006

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: A-1, B-1
A-1 pertains to Phase 1; B-1 pertains to Phase 2
Drug: trandolapril
2 mg QD
Other Names:
  • ABT-878
  • Mavik/Gopten
Active Comparator: A-2, B-2
A2 pertains to Phase 1; B-2 pertains to Phase 2
Drug: trandolapril/verapamil
180/2 mg QD
Other Names:
  • VeraTran
  • Tarka
Placebo Comparator: A-3 Drug: placebo
1 tablet QD
Active Comparator: A-4 Drug: verapamil
SR 240 mg QD
Other Name: ABT-150

Primary Outcome Measures :
  1. Phase A: microalbuminuria; Phase B: progression from microalbuminuria to macroalbuminuria. [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. Course of albumin excretion over time, GFR, blood pressure (BP), incidence of major CV events, overall and CV mortality, HbA1c, progression of retinal changes. [ Time Frame: 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 2 Diabetes
  • Hypertension

Exclusion Criteria:

  • Albuminuria (Phase A)
  • Non-diabetic renal disease
  • Subject has a hypersensitivity to ACE inhibitor, CCB

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00235014

Sponsors and Collaborators
Study Director: Global Medical Information 1-800-633-9110 Abbott

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Udo Legler, MD, Abbott
ClinicalTrials.gov Identifier: NCT00235014     History of Changes
Other Study ID Numbers: VeraTran 083
First Posted: October 10, 2005    Key Record Dates
Last Update Posted: July 15, 2008
Last Verified: June 2008

Keywords provided by Abbott:

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Anti-Arrhythmia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Antihypertensive Agents